Ian Tomlinson has over 25 years of experience in the lifesciences sector from academic research to biotech startup to big pharma. He founded Domantis Limited with Sir Gregory Winter, which was acquired by GSK for $454million. He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK.
He is currently Chairman of the Board at the Stevenage Bioscience Catalyst, UK's first open innovation biomedical campus. He is also Chairman of the Investment Committee for Apollo Therapeutics, a £40 million fund dedicated to turning academic biotechnologies into novel medicines in collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge.
Dr Tomlinson graduated from Trinity College, Cambridge, UK. He then spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry.